NeurAxis, Inc.
AMEX:NRXS · New York Stock Exchange American
+$0.29 today
Vol 0.13M · Avg 0.18M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-229.5%
avg 106.7%
ROIC
-204.7%
avg 117.4%
ROA
-121.8%
avg -670.1%
Analysis
ROA is currently the strongest return metric at -121.8% versus its period average of -670.1%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Brian Carrico | President, Chief Executive Officer & Director | $547,598.00 | — | 44 | $348,178.00 | 2.81% |
Timothy Robert Henrichs | Chief Financial Officer | $489,423.00 | — | 53 | $7,593.00 | 0.06% |
Thomas Carrico | Chief Regulatory Officer and Compliance & Privacy Officer | $400,575.00 | — | 69 | $348,178.00 | 2.81% |
Adrian Miranda | Senior Vice President of Science & Technology and Chief Medical Officer | $399,069.00 | — | 56 | $47,569.00 | 0.38% |
Behnam Shamsian | Investor Relations | — | — | — | — | — |
Christopher Robin Brown | Founder, Director of Innovation & Director | — | — | 72 | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
4
$1.04M
Sells
1
$652,002.75
Net Sentiment
+$387,190.21
Net buying
Most Active
Henrichs Timothy Robert
1 transactions
Analysis
Insiders reported 4 buys worth $1.04M and 1 sells worth $652,002.75 over the last 12 months. That adds up to net buying of $387,190.21. Henrichs Timothy Robert was the most active insider with 1 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | -0.4% | +86.9% (4yr)1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Recent growth has been strongest in Revenue at -0.4% over three years. Forward estimates point to Revenue at +86.9% (4yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Rallybio Corporation
NASDAQ:RLYB
$92.36M
Minerva Neurosciences, Inc.
NERV
$29.51M
Klotho Neurosciences, Inc.
KLTO
$20.08M
NeuroSense Therapeutics Ltd.
NRSN
$18.50M
Exicure, Inc.
XCUR
$15.52M
Enlivex Therapeutics Ltd.
ENLV
$15.06M
TAO Synergies Inc.
TAOX
$12.15M
Cadrenal Therapeutics, Inc. Common Stock
CVKD
$9.35M
Sonnet BioTherapeutics Holdings, Inc.
SONN
$8.43M
CollPlant Biotechnologies Ltd.
CLGN
$4.03M
Who manages NRXS?
NeurAxis, Inc. (NRXS) lists 6 active executives. The top listed executive is Thomas Carrico, Chief Regulatory Officer and Compliance & Privacy Officer.
Are NRXS insiders buying or selling?
Recent insider activity shows net buying of $899,561.61.
Explore More
Continue the stock analysis
Jump to another research area for this company.